Zacks.com on MSN14h
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?Shares of Sarepta Therapeutics SRPT have soared 43% year to date, significantly outperforming the industry’s 6.9% decline.
Bernstein lowered the firm’s price target on Arrowhead (ARWR) to $24 from $27 and keeps a Market Perform rating on the shares. The company’s ...
On Wednesday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $137.94 which represents a slight increase of $7.44 or 5.70% from the prior close of $130.5. The stock opened ...
Investor's Business Daily on MSN17h
Sarepta Therapeutics Sees RS Rating Rise To 75A Relative Strength Rating upgrade for Sarepta Therapeutics shows improving technical performance. Will it continue?
The head of MI6 says British security will be "jeopardised" if Putin is allowed to succeed in Ukraine, as he warned the spy agency has already uncovered a Russian sabotage campaign in Europe.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback